World Health Organization experts will visit Kenya to examine the nation's drug regulation improvements. The Pharmacy and Poisons Board faces evaluation on inspection procedures, safety monitoring systems, digital platforms, and partnership coordination. Kenya seeks Maturity Level 3 recognition, which demonstrates that regulators maintain consistent safety and quality standards for medications.
Principal Secretary Mary Muthoni discussed the assessment with WHO Acting Representative Dr Adiele Onyeze on Wednesday. She previously engaged with Pharmaceutical Society President Dr Wairimu Njuki to strengthen professional partnerships. The government plans to advance two key pharmaceutical bills and establish a Bioequivalence Hub for local manufacturing support. Officials aim to expand pharmacist roles in supply chain management and public health initiatives.
The evaluation involves PPB leadership and senior health ministry representatives. Achievement of this regulatory milestone would position Kenya among elite African nations with advanced oversight capabilities, boosting international confidence in the country's pharmaceutical monitoring systems.
Principal Secretary Mary Muthoni discussed the assessment with WHO Acting Representative Dr Adiele Onyeze on Wednesday. She previously engaged with Pharmaceutical Society President Dr Wairimu Njuki to strengthen professional partnerships. The government plans to advance two key pharmaceutical bills and establish a Bioequivalence Hub for local manufacturing support. Officials aim to expand pharmacist roles in supply chain management and public health initiatives.
The evaluation involves PPB leadership and senior health ministry representatives. Achievement of this regulatory milestone would position Kenya among elite African nations with advanced oversight capabilities, boosting international confidence in the country's pharmaceutical monitoring systems.
